Evolution of pathogenetic therapy of pulmonary arterial hypertension
- Authors: Chazova IE1, Yarovoy SY.1, Danilov NM1
-
Affiliations:
- National Medical Research Center of Cardiology
- Issue: Vol 91, No 12 (2019)
- Pages: 4-9
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33725
- DOI: https://doi.org/10.26442/00403660.2019.12.000475
- ID: 33725
Cite item
Full Text
Abstract
Pulmonary arterial hypertension (PAH) is a severe, disabling disease characterized by an increase pressure in the pulmonary artery (PA), an increase pressure in the right atrium, and a decrease of the cardiac output. It combines several diseases: idiopathic pulmonary hypertension, inherited pulmonary hypertension, PAH induced by medication and toxins, PAH associated with systemic diseases of connective tissue, HIV infection, portal hypertension, congenital heart defects, schistosomiasis. In the absence of treatment, PAH quickly leads to insufficiency of the right heart and premature death. An effective PAH therapy did not exist for a long time. However, in 1987 there was established a positive effect of taking large doses of calcium channel blockers in patients, who “responded” to their prescription in the short term, and in recently several groups of specific drugs have been developed and approved for the treatment of this pathology: prostacyclin analogues and prostacyclin receptors agonists, endothelin receptor antagonists, phosphodiesterase type 5 inhibitors and soluble guanylate cyclase stimulators. Modern studies of treatment of PAH are based on the latest data of the molecular transmission mechanisms of intracellular and intercellular signals, the action of hormones and tissue enzymes. The available results of these studies allow to suggest the inclusion to clinical guidelines several new drugs for the pathogenetic treatment of PAH in the near future: receptor tyrosine kinase inhibitors, Rho - kinase inhibitors, immunosuppressants and type 2 activin receptor agonists, protein kinase C inhibitors, aromatase inhibitors and estrogen receptor antagonists, poly-(ADP-ribose)-polymerase inhibitors and bromodomain protein 4, elastase inhibitors. Some of the drugs have already passed the III phase of clinical trials (imatinib), others are at the preclinical stage or at the I-II phase tests (olaparib, enzastaurin, elafin).
Full Text
##article.viewOnOriginalSite##About the authors
I E Chazova
National Medical Research Center of CardiologyMoscow, Russia
S Yu Yarovoy
National Medical Research Center of CardiologyMoscow, Russia
N M Danilov
National Medical Research Center of CardiologyMoscow, Russia
References
- Чазова И.Е., Мартынюк Т.В. Клинические рекомендации по диагностике и лечению хронической тромбоэмболической легочной гипертензии (II часть). Терапевтический архив. 2016;88(10):63-73. doi: 10.17116/ter-arkh201688663-73
- Валиева З.С., Таран И.Н., Мартынюк Т.В., Чазова И.Е. Современный взгляд на место риоцигуата в лечении легочной гипертензии. Терапевтический архив. 2018;90(4):55-9. doi: 10.26442/terarkh201890455-59
- Dannewitz Prosseda S, Tian X, Kuramoto K, et al. FHIT, a Novel Modifier Gene in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2019;199(1):83-98. doi: 10.1164/rccm.201712-2553oc
- Wang Y, Li Y, Ding X, et al. 17β - estradiol preserves right ventricular function in rats with pulmonary arterial hypertension: an echocardiographic and histochemical study. Int J Cardiovasc Imaging. 2018;35(3):441-50. doi: 10.1007/s10554-018-1468-0